Last reviewed · How we verify
hydrocodone / acetaminophen extended release
Hydrocodone is an opioid agonist that binds to opioid receptors in the brain, while acetaminophen is a non-opioid analgesic that works by inhibiting the production of prostaglandins.
Hydrocodone is an opioid agonist that binds to opioid receptors in the brain, while acetaminophen is a non-opioid analgesic that works by inhibiting the production of prostaglandins. Used for Management of moderate to severe pain.
At a glance
| Generic name | hydrocodone / acetaminophen extended release |
|---|---|
| Also known as | ABT-712 |
| Sponsor | Abbott |
| Drug class | Opioid agonist / non-opioid analgesic |
| Target | Opioid receptors |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 3 |
Mechanism of action
The combination of hydrocodone and acetaminophen provides effective pain relief by targeting multiple pathways in the central nervous system. Hydrocodone's opioid agonist activity is responsible for its analgesic and euphoric effects, while acetaminophen's non-opioid mechanism helps to reduce the risk of opioid-related side effects.
Approved indications
- Management of moderate to severe pain
Common side effects
- Constipation
- Dizziness
- Nausea
- Vomiting
- Headache
- Somnolence
- Fatigue
- Dry mouth
- Sedation
- Pruritus
Key clinical trials
- Hip Arthroscopy Postoperative Opioid Demands (NA)
- A Multicenter Active Comparator Study of HC-ER in Adults Following Bunionectomy Surgery (PHASE2)
- Analgesia After Total Knee Arthroplasty: Peri-Articular Injection Versus Epidural + Femoral Nerve Blockade (PHASE4)
- Liposomal Bupivacaine in Implant Based Breast Reconstruction (NA)
- Study of COV795 in Subjects With Osteoarthritis or Chronic Low Back Pain (PHASE3)
- Pharmacokinetics (PK) and Safety Study of XARTEMIS® XR in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain (PHASE4)
- A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine (PHASE4)
- Single Dose Pharmacokinetics of Egalet® Hydrocodone (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- hydrocodone / acetaminophen extended release CI brief — competitive landscape report
- hydrocodone / acetaminophen extended release updates RSS · CI watch RSS
- Abbott portfolio CI